Summary
The possibility of a pharmacokinetic interaction between two hypolipidemic drugs, colestipol, an ion exchange resin, and fenofibrate, a phenoxyacid derivative, was studied in 6 male volunteers. The investigation followed a four-step protocol during 18 days, and relied on determination of plasma and urinary levels of fenofibric acid, the active metabolite of fenofibrate. The kinetics of a single dose of fenofibrate 300 mg was established over 3 days. Thereafter, from Days 4 to 9 fenofibrate was given daily as 200 mg in the morning and 100 mg in the evening; the plasma fenofibric acid level reached about 10 µg/ml. From Days 9 to 15 the same dose of fenofibrate was administered together with colestipol 10 g in the morning and 5 g in the evening. Plasma fenofibric acid concentrations remained unchanged and the 24 h urinary excretion of fenofibric acid did not fall. On Day 15, a last single dose of fenofibrate 300 mg was given with colestipol 15 g. The pharmacokinetic pattern of fenofibric acid on Days 15 to 18 did not differ significantly from that found previously (Days 1 to 3). From these results, it is likely that there is no pharmacokinetic interaction between the two hypolipidemic drugs.
Similar content being viewed by others
References
Harvengt C, Desager JP (1978) Colestipol in familial type II hyperlipoproteinemia: a three year trial. Clin Pharmacol Ther 20: 310–314
Harvengt C, Heller F, Desager JP (submitted for publication) (1980) Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias Artery
Desager JP, Hulhoven R, Harvengt C (in press) Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol
Ko H, Royer ME (1974) In vitro binding of drugs to colestipol hydrochloride. J Pharm Sci 63: 1914–1920
Harvengt C, Desager JP (1973) Effect of colestipol, a new bile acid sequestrant, on the absorption of phenprocoumon in man. Europ J Clin Pharmacol 6: 19–21
Desager JP (1978) Gas-liquid chromatographic determination of procetofenic acid in human plasma and urine. J Chromatogr 145: 160–164
Desager JP, Harvengt C (1978) Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol Biopharm 16: 570–574
Sedaghat A, Ahrens EJ Jr (1975) Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man. Eur J Clin Invest 5: 177–185
Goodman DS, Noble RP, Dell RB (1973) The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man. J Clin Invest 52: 2646–2655
Desante KA, Disanto AR, Albert KS, Welch RD, Vecchio TJ (1978) The effect of colestipol hydrochloride or cholestyramine on the bioavailability and pharmacokinetics of clofibrate. Clin Pharmacol Ther 23: 112
Sauvanet JP, Drouin P, Debry G, Mejean L, Lamberg D (1978) Hyperlipoprotéinémies de type II. Traitement par colestipol et procétofène. Nouv Presse Med 21: 1862–1863
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harvengt, C., Desager, J.P. Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers. Eur J Clin Pharmacol 17, 459–463 (1980). https://doi.org/10.1007/BF00570164
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00570164